<DOC>
	<DOCNO>NCT00640965</DOCNO>
	<brief_summary>The study evaluate DP-VPA , derivative valproate ( drug commonly use prevention migraine attack ) , reduce rate migraine attack . Migraine patient take DP-VPA placebo ( inactive look-alike drug ) every morning report migraine attack study 's 18-week follow .</brief_summary>
	<brief_title>DP-VPA Migraine Prophylaxis , Pilot Efficacy Study</brief_title>
	<detailed_description>The multi-center trial double-blind , randomize , placebo-controlled , parallel-group design carry Israel . Approximately 40 adult subject migraine randomly assign ( 1:1 ) either DP-VPA ( maximum 900mg/day ) placebo . Active placebo administer orally once-daily add-on basis , i.e . permissible ongoing medication continue . Total study duration per subject 18 week . Subjects report migraine attack frequency attack characteristic use weekly diary .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Inclusion criterion ( abridge ) Male female subject migraine without aura fulfil diagnostic criterion International Classification Headache Disorders 3 6 migraine attack per month Concomitant prophylactic migraine treatment betablocker amitriptyline stable proceed 3 month . No change concomitant treatment allow end study followup . Exclusion criterion ( abridge ) Chronic migraine ( &gt; 15 day migraine/ month ) . Migraine complicate medicationoveruse headache . Allergy hypersensitivity valproic acid , valproate sodium , soy . Known contraindication valproic acid . Pregnancy . Breastfeeding female subject . Subjects significant hepatic dysfunction indicate SGOT SGPT &gt; 3 time upper limit normal screening . Renal impairment indicate serum creatinine &gt; 1.5mg/dL screening . Potentially fertile sexually active woman practice reliable contraception . Men practice reliable barrier contraception . Concomitant use antipsychotic , antidepressant antiepileptic therapy exception amitriptyline within 1 month screening , medical condition likely require treatment trial participation . An active central nervous system disease deem unstable progressive course study may confound interpretation study result . Any medical disorder may make subject unlikely fully complete study Blood coagulation disorder . Concomitant drug know interact VPA . Alcohol drug abuse . Therapy another investigational product within 30 day prior start study . Concomitant participation another trial study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>